A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease

• Pulmonary Disease, Chronic Obstructive
• Lung Diseases
• Respiratory Tract Diseases
• Chronic Obstructive Airway Disease
• COPD

• Drug: placebo
  oral inhaled formulation, single dose
• Drug: active comparator
  oral inhaled formulation, single dose
• Drug: Low Dose PF-03635659
  oral inhaled formulation, single dose, low dose
• Drug: Mid Dose PF-03635659
  oral inhaled formulation, single dose, mid dose
• Drug: High Dose PF-03635659
  oral inhaled formulation, single dose, high dose

• Placebo Comparator: Placebo
  Intervention: Drug: placebo
• Active Comparator: active comparator
  Intervention: Drug: active comparator
• Experimental: PF-03635659
  Interventions:

  • Drug: Low Dose PF-03635659
  • Drug: Mid Dose PF-03635659
  • Drug: High Dose PF-03635659

Inclusion Criteria:

• Male or female (women of non-childbearing potential) subjects between the ages of 40 and 80 years, inclusive with a diagnosis of moderate COPD (GOLD, 2007 update) and who meet the following criteria for GOLD stage II disease
• Body Mass Index (BMI) of less than 35.5 kg/m2; and a total body weight >40 kg (88 lbs).
• Current smokers, or ex-smokers who have abstained from smoking for at least 6 months

Exclusion Criteria:

• Subjects having more than 2 exacerbations requiring treatment with oral steroids or hospitalization for the treatment of COPD in the previous year.
• History of lower respiratory tract infection or significant disease instability during the month preceding screening or during the period between screening and randomization.